Healthcare & Life Sciences

Kamari Pharma

Sign in to unlock

About

Kamari Pharma develops proprietary small molecule inhibitors of the TRPV3 cation channel expressed primarily in keratinocytes, targeting dermatological conditions with unmet medical needs.

Explore Kamari Pharma's full profile on Brouky

Funding rounds, investor list, and risk signals — unlock with a subscription.

Sign in to unlockView pricing